Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act

References

• United Nations Office on Drugs and Crime. World drug report 2017 (ISBN: 978-92-1-148291-1, eISBN: 978-92-1-060623-3). Sales No. E.17.XI.6. New York (NY): United Nations Publication; 2017.
   Google Scholar
• Bretteville-Jensen AL, Tuv SS, Bilgrei OR, et al. Synthetic cannabinoids and cathinones: prevalence and markets. Forensic Sci Rev. 2013;25:7–26.
   PubMedGoogle Scholar
• Zuba D, Byrska B. Prevalence and co-existence of active components of 'legal highs'. Drug Test Anal. 2013;5:420–429.
   PubMed Web of Science ®Google Scholar
• Logan BK, Mohr ALA, Friscia M, et al. Reports of adverse events associated with use of novel psychoactive substances, 2013-2016: a review. J Anal Toxicol. 2017;41:573–610.
   PubMed Web of Science ®Google Scholar
• Wood DM, Heyerdahl F, Yates CB, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2014;52:239–241.
   PubMed Web of Science ®Google Scholar
• Wood DM, Ceronie B, Dargan PI. Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs. QJM 2016;109:527–529.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Chris W. ‘Legal highs’: the challenge of new psychoactive substances. TNI/IDPC Transnational Institute Series on Legislative Reform of Drug Policies No. 16. London, United Kingdom: International Drug Policy Consortium; 2011.
   Google Scholar
• Home Office of the United Kingdom. New psychoactive substances review: report of the expert panel [accessed February 2018, cited September 2014]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/368583/NPSexpertReviewPanelReport.pdf
   Google Scholar
• Home Office of the United Kingdom. Psychoactive Substances Act 2016 [accessed February 2018]. Available from: https://www.gov.uk/government/collections/psychoactive-substances-bill-2015.
   Google Scholar
• Rychert M, Wilkins C, Witten K. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand. Drug Alcohol Rev. 2017;36:589–596.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction and Europol. Legal approaches to controlling new psychoactive substances. Luxembourg: EMCDDA–Europol Joint publications, Publications Office of the European Union; 2016.
   Google Scholar
• Greene SL, Wood DM, Gawarammana IB, et al. Improvement in the management of acutely poisoned patients using an electronic database, prospective audit and targeted educational intervention. Postgrad Med J. 2008;84:603–608.
   PubMed Web of Science ®Google Scholar
• Haden M, Wood DM, Dargan PI. The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA. QJM 2017;110:619–622.
   PubMed Web of Science ®Google Scholar
• Home Office of the United Kingdom. Drug misuse: Findings from the 2015/2016 crime survey for England and Wales. 2nd ed. [accessed February 2018]. 2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/564760/drug-misuse-1516.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: trends and developments. Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• Reuter P, Pardo B. New psychoactive substances: are there any good options for regulating new psychoactive substances? Int J Drug Policy 2017;40:117–122.
   PubMed Web of Science ®Google Scholar
• Home Office of the United Kingdom and Sarah Newton MP. News story: headshops closed and offenders arrested after ‘legal highs’ ban [accessed February 2018]. 2016. Available from: https://www.gov.uk/government/news/headshops-closed-and-offenders-arrested-after-legal-highs-ban
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction and Europol. Drugs and the darknet: perspectives for enforcement, research and policy. Luxembourg: EMCDDA–Europol Joint publications, Publications Office of the European Union; 2017.
   Google Scholar
• Heyerdahl F, Hovda KE, Giraudon I, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol. 2014;52:1005–1012.
   PubMed Web of Science ®Google Scholar
• Dines AM, Wood DM, Yates C, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53:893–900.
   PubMed Web of Science ®Google Scholar
• Wood DM, Greene SL, Dargan PI. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J. 2013;30:70–71.
   PubMed Web of Science ®Google Scholar
• Archer JRH, Dargan PI, Hudson S, et al. 4-Year surveillance trends of new psychoactive substances in London, UK using pooled urine analysis. 38th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) (abstract accepted for publication in Clinical Toxicology in 2018). 2018 May 24. Bucharest, Romania.
   Google Scholar
• Zawilska JB. Mephedrone and other cathinones. Curr Opin Psychiatry 2014;27:256–262.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Recent changes in Europe’s MDMA/ecstasy market. EMCDDA rapid communication. Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• Mounteney J, Griffiths P, Bo A, et al. Nine reasons why ecstasy is not quite what it used to be. Int J Drug Policy 2018;51:36–41.
   PubMed Web of Science ®Google Scholar
• Home Office of the United Kingdom. Drug misuse declared: findings from the 2011/12 crime survey for England and Wales. 2nd ed. (accessed February 2018). 2012. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147938/drugs-misuse-dec-1112-pdf.pdf
   Google Scholar
• Home Office of the United Kingdom. Drug misuse: findings from the 2016/2017 crime survey for England and Wales (accessed February 2018). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/642738/drug-misuse-2017-hosb1117.pdf
   Google Scholar
• Zaurova M, Hoffman RS, Vlahov D, et al. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol. 2016;12:335–340.
   PubMed Web of Science ®Google Scholar
• Ralphs R, Williams L, Askew R, et al. Adding spice to the porridge: the development of a synthetic cannabinoid market in an English prison. Int J Drug Policy 2017;40:57–69.
   PubMed Web of Science ®Google Scholar
• Home Office Circular 21/2009. A change to the Misuse of Drugs Act 1971: Control of GBL, 1,4-BD, BZP and related piperazine compounds, a further group of anabolic steroids and 2 non-steroidal agents, synthetic cannabinoid receptor agonists and oripavine. 2009. Available from: http://library.college.police.uk/docs/hocirc/ho-circ-2009-021-control-of-gbl.pdf
   Google Scholar
• Dargan PI, Hudson S, Ramsey J, et al. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int J Drug Policy 2011;22:274–277.
   PubMed Web of Science ®Google Scholar
• Kikura-Hanajiri R, Kawamura NU, Goda Y. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal. 2014;6:832–839.
   PubMed Web of Science ®Google Scholar
• Advisory Council on the Misuse of Drugs. ‘Third generation’ synthetic cannabinoids. 2014. (accessed February 2018). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf
   Google Scholar
• Hermanns-Clausen M, Muller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol. 2018;56:404–411.
   PubMed Web of Science ®Google Scholar
• Abdulrahim D, Bowden-Jones O, on behalf of NEPTUNE group. Harms of synthetic cannabinoid receptor agonists (SCRAs) and their management. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 2016.
   Google Scholar
• Public Health England. National poisons information service report 2016/2017. England: PHE publications; 2017.
   Google Scholar
• Vallersnes OM, Persett PS, Oiestad EL, et al. Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway. Clin Toxicol. 2017;55:636–644.
   PubMed Web of Science ®Google Scholar
• Abouchedid R, Hudson S, Thurtle N, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol. 2017;55:338–345.
   PubMed Web of Science ®Google Scholar
• Arkes J. Recessions and the participation of youth in the selling and use of illicit drugs. Int J Drug Policy 2011;22:335–340.
   PubMed Web of Science ®Google Scholar